HUMAN DISEASE MODELED by nz50Tg

Human Disease	Conditions	Citations
bacterial infectious disease	bacterial treatment by injection: Pseudomonas aeruginosa PAK	McCarthy et al., 2017
	bacterial treatment by injection: Staphylococcus aureus	Ulhuq et al., 2020
inflammatory bowel disease	chemical treatment by environment: 2,4,6-trinitrobenzenesulfonic acid	Yu et al., 2021

GENE EXPRESSION
Gene expression in nz50Tg

PHENOTYPE
Phenotype in nz50Tg

Phenotype	Conditions	Figures
blood island neutrophil normal amount, normal	bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium	Fig. 3  from Oehlers et al., 2011
hindbrain neutrophil increased amount, abnormal	bacterial treatment by injection: Pseudomonas aeruginosa PAK	Fig. 5 from McCarthy et al., 2017
hindbrain neutrophil increased amount, abnormal	bacterial treatment by injection: Staphylococcus aureus	Fig. S8 from Ulhuq et al., 2020
inflammatory response increased occurrence, abnormal	resection: caudal fin	Fig. 2  from Antonio et al., 2015
inflammatory response to wounding increased process quality, abnormal	laceration: ventral fin fold	Fig. 3 ,  Fig. 4  from Wittmann et al., 2015
inflammatory response to wounding increased process quality, ameliorated	laceration: ventral fin fold, chemical treatment: 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one	Fig. 3  from Wittmann et al., 2015
inflammatory response to wounding increased process quality, ameliorated	laceration: ventral fin fold, chemical treatment: EC 1.14.13.39 (nitric oxide synthase) inhibitor	Fig. 3  from Wittmann et al., 2015
inflammatory response to wounding increased process quality, ameliorated	laceration: ventral fin fold, chemical treatment: N(gamma)-nitro-L-arginine methyl ester hydrochloride	Fig. 3  from Wittmann et al., 2015
intestine morphology, abnormal	chemical treatment by environment: 2,4,6-trinitrobenzenesulfonic acid	Fig. 2  from Yu et al., 2021
intestine neutrophil increased amount, abnormal	chemical treatment by environment: 2,4,6-trinitrobenzenesulfonic acid	Fig. 2  from Yu et al., 2021
intestine reactive oxygen species increased amount, abnormal	chemical treatment by environment: 2,4,6-trinitrobenzenesulfonic acid	Fig. 2  from Yu et al., 2021
leukocyte nitric-oxide synthase activity increased process quality, abnormal	bacterial treatment	Fig. 5  from Elks et al., 2013
liver neutrophil increased amount, abnormal	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
liver neutrophil increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 1 from Yan et al., 2017
male organism neutrophil htr2b expression increased amount, abnormal	standard conditions	Fig. 3  from Yang et al., 2017
neutrophil decreased amount, abnormal	bacterial treatment by injection: Shigella flexneri	Fig. 3  from Mazon-Moya et al., 2017
neutrophil increased amount, abnormal	resection: caudal fin	Fig. 2  from Antonio et al., 2015
neutrophil normal amount, normal	chemical treatment: pharmaceutical	Fig. 3  from Herbst et al., 2015
neutrophil cell population proliferation increased occurrence, abnormal	chemical treatment by environment: 1,4-benzoquinone	Fig. 3  from Zhang et al., 2019
neutrophil nuclear envelope Ab2-lmnb2 labeling absent, abnormal	chemical treatment by environment: EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	Fig. 5 from Bowes et al., 2019
neutrophil chemotaxis decreased process quality, abnormal	amputation: caudal fin, chemical treatment: U-73122	Fig. 1 from de Oliveira et al., 2014
neutrophil chemotaxis decreased process quality, abnormal	amputation: caudal fin, chemical treatment: dibenziodolium chloride	Fig. 2 from de Oliveira et al., 2014
neutrophil chemotaxis decreased process quality, abnormal	amputation: caudal fin, chemical treatment: suramin sodium	Fig. 1 from de Oliveira et al., 2014
neutrophil chemotaxis decreased process quality, abnormal	amputation: caudal fin, chemical treatment: tetrasodium 5'-phosphonatopyridoxal-6-azobenzene-2,4-disulfonate	Fig. 1 from de Oliveira et al., 2014
neutrophil chemotaxis decreased process quality, abnormal	amputation: caudal fin, chemical treatment: thapsigargin	Fig. 1 from de Oliveira et al., 2014
neutrophil chemotaxis decreased process quality, abnormal	amputation: caudal fin, chemical treatment: adenosine phosphate	Fig. 1 from de Oliveira et al., 2014
response to fungus disrupted, abnormal	chemical treatment: tacrolimus (anhydrous), fungal treatment by injection: Aspergillus fumigatus	Fig. 3  from Herbst et al., 2015
response to fungus process quality, normal	fungal treatment by injection: Aspergillus fumigatus	Fig. 3  from Herbst et al., 2015
swim bladder neutrophil increased amount, abnormal	bacterial treatment by injection: Waddlia chondrophila WSU 86-1044	Fig. 5  from Fehr et al., 2016
tumor necrosis factor-mediated signaling pathway disrupted, abnormal	chemical treatment: tacrolimus (anhydrous), fungal treatment by injection: Aspergillus fumigatus	Fig. 3  from Herbst et al., 2015
ventral wall of dorsal aorta neutrophil increased amount, abnormal	bacterial treatment: Salmonella enterica subsp. enterica serovar Typhimurium	Fig. 5  from Hall et al., 2012
whole organism dead, abnormal	bacterial treatment by injection: Staphylococcus aureus	Fig. 5,  Fig. S5 from Ulhuq et al., 2020
whole organism dead, abnormal	fungal treatment by injection: Aspergillus fumigatus	Fig. 3  from Herbst et al., 2015
whole organism dead, abnormal	chemical treatment: tacrolimus (anhydrous), fungal treatment by injection: Aspergillus fumigatus	Fig. 3  from Herbst et al., 2015
whole organism decreased life span, abnormal	bacterial treatment by injection: Staphylococcus aureus	Fig. 5,  Fig. S5 from Ulhuq et al., 2020
whole organism viability, abnormal	bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium	Fig. 2  from Oehlers et al., 2011